AirNet Technology raises $180 million in digital assets offering
CHICAGO—Frederick Wayne, a director at Tempus AI , Inc. (NASDAQ:TEM), recently sold a significant portion of his holdings in the company. According to a Form 4 filing with the Securities and Exchange Commission, Wayne disposed of a total of 9,000 shares of Tempus AI Class A Common Stock on March 17, 2025. The shares were sold at prices ranging from $46.69 to $50.62, amounting to a total transaction value of approximately $439,658. The stock, currently trading at $48.03, has shown strong momentum with a 42% gain year-to-date, though InvestingPro analysis indicates the shares may be overvalued at current levels.
This transaction was carried out under a Rule 10b5-1 trading plan, which Wayne adopted on September 12, 2024. Following these sales, Wayne now holds 29,514 shares in the company. According to InvestingPro data, the company maintains healthy liquidity with a current ratio of 2.29, though it remains unprofitable with negative EBITDA of $653.76 million in the last twelve months.
Tempus AI, headquartered in Chicago, specializes in computer programming and data processing services. The company, formerly known as Tempus Labs, Inc., continues to be a key player in the technology sector. For deeper insights into TEM’s financial health and growth prospects, investors can access comprehensive analysis and 7 additional key tips through InvestingPro’s detailed research reports.
In other recent news, Tempus AI reported a significant 35.8% increase in revenue for the fourth quarter of 2024, reaching $700 million. Despite this revenue growth, the company posted a negative earnings per share (EPS) of -0.18. Tempus AI has also revised its 2025 revenue guidance to approximately $1.24 billion, including contributions from the recent acquisition of Ambry Genetics. The acquisition of Deep 6 AI is another strategic move by Tempus AI, aimed at enhancing its capabilities in AI-driven research platforms for healthcare. This acquisition is expected to expand Tempus’s network and improve its applications, such as those assisting in clinical trials and patient care optimization.
Analyst firms have made notable adjustments to their ratings for Tempus AI. Stifel maintained a Hold rating with a $65 price target, while JPMorgan downgraded the stock from Overweight to Neutral but raised the price target to $55. JPMorgan’s analysis highlights Tempus AI’s sustainable data and service revenue, alongside encouraging profitability trends. Despite some concerns about a slight revenue shortfall in non-core business areas, Tempus AI’s core business is expected to grow by over 30% year-over-year.
Furthermore, the company has launched the Olivia AI personal health app, aiming to provide patients with a personalized health management tool. As Tempus AI continues to expand its operations and product offerings, these developments reflect the company’s ongoing efforts to strengthen its position in the healthcare technology sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.